Cold-Shock Protein Scaffolds for Stable Intracellular Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibody-based technologies face challenges in targeting intracellular molecules due to their large size and stability issues, limiting their effectiveness in diagnostic and therapeutic applications, while protein scaffolds like Affibody® polypeptides suffer from immunogenicity and insufficient stability.
Innovation Solution
Development of recombinant binding protein scaffolds based on cold-shock proteins or cold shock domains, including chimeric polypeptides with mutations, for targeted delivery and enhanced stability, and the use of polypeptide display libraries for screening and selecting molecules with desired binding affinity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If antibody-based technologies are used for targeting intracellular molecules, then high specificity to targets is achieved, but the large size and disulfide linkages restrict access to targets within the cytoplasm
Solution Approach 1:
The invention divides the antibody structure into a smaller protein scaffold core with engineered binding domains, creating compact molecules that can penetrate cellular structures while maintaining target recognition capabilities. The segmented design allows the binding function to be separated from the large antibody framework.
Solution Approach 2:
The patent employs small, transiently expressed protein scaffolds that can be rapidly synthesized and degraded, replacing long-lived antibodies with shorter-lived, smaller molecules that are better suited for intracellular delivery and rapid turnover in cytoplasmic environments.
2Measurement precision
If antibody-based technologies are used, then high specificity is achieved, but stability is reduced due to rapid degradation resulting in short shelf-life
Solution Approach 1:
The invention changes the structural parameters of the binding molecule by using stable protein scaffold cores with engineered binding domains, altering the molecular properties to achieve both high specificity and enhanced stability against degradation compared to conventional antibodies.
Solution Approach 2:
The patent creates composite protein structures by combining stable scaffold cores with engineered binding domains, resulting in hybrid molecules that inherit the stability of the scaffold while acquiring the target-specific binding capabilities needed for diagnostic applications.
3Length of moving object
If protein scaffolds like Affibody® polypeptides are used, then short peptide chains are achieved for quick renal clearance and sensing applications, but immunogenicity increases due to derivation from proteins without human analog
Solution Approach 1:
The invention applies local quality by using human cold shock protein domains as the scaffold core, ensuring that the fundamental structural framework is derived from a human protein to reduce immunogenicity, while only the binding domains are engineered for specific target recognition.
Solution Approach 2:
The patent employs homogeneity by deriving the scaffold from human proteins, creating molecules that are more structurally and immunologically similar to endogenous human proteins, thereby reducing the immune response while maintaining the desired short peptide chain characteristics.
4Productivity
If protein scaffolds like Affibody® polypeptides are used, then quick renal clearance and sensing capability are achieved, but stability is insufficient for many potential applications
Solution Approach 1:
The invention changes the stability parameters by selecting protein scaffold cores from extremophiles or highly stable human proteins, fundamentally altering the thermal and chemical stability characteristics while preserving the small size needed for rapid renal clearance and sensing applications.
Data Source
AI summary
Disclosed herein are compositions and methods directed to non-antibody protein scaffolds derived from cold-shock proteins.